When it became clear that several serious, mortal, and mostly untreatable rare diseases were due to defects in peroxisomes and that plasmalogen deficiency alone is sufficient to cause mortality and morbidity in these diseases, research into the biochemical pathways necessary for the biosynthesis of plasmalogens was intensified. The peroxisomal biosynthesis of plasmalogens was (and still is) believed to end at the formation of the alkyl ether bond and then 1-alkyl-glyceryl-3-phosphate exits the peroxisome and goes on to the endoplasmic reticulum for the final steps. Based upon this logic, a simple alkylglycerol such as chimyl, batyl, or selachyl alcohol should be able to restore plasmalogen levels in plasmalogen deficient cells, animals, and humans. To a certain degree this is true, however high doses are needed and only partial recovery can be obtained.
To access the FREE seminars with full presentations and videos please visit Dr. Goodenowe’s resource site here. This is the article for Lecture 11 – The Biochemistry of Plasmalogen Supplementation, of Breaking Alzheimer’s – The Definitive Lecture Series.
When Dr. Goodenowe discovered that a systemic deficiency in plasmalogens was present in Alzheimer’s disease, dementia, and cancer, he began to research the mechanisms of plasmalogen restoration in greater detail than any other researcher before him. Dr. Goodenowe’s research revealed that to effectively elevate plasmalogen levels, the plasmalogen supplement must contain a fatty acid at the sn-2 position. These metabolites are called 1-O-alkyl-2-acyl-glycerols. Dr. Goodenowe was the first to invent these precursors and show that are dramatically more effective than simple alkylglycerols at elevating plasmalogens.
There are multiple types of plasmalogens in the human body and different plasmalogens are found in different locations. For example, the myelin sheath that surrounds and protects the neuronal axons of the body contain high levels of monounsaturated plasmalogens whereas the neuronal synapse region contains high levels of polyunsaturated plasmalogens. Dr. Goodenowe also discovered that by making plasmalogen precursors with specific fatty acids at the sn-2 position, that he could selectively enhance specific types of plasmalogens. Dr. Goodenowe’s plasmalogen supplements are the only plasmalogen supplements that can do this.
Dr. Goodenowe’s plasmalogen supplements have been extensively studied in laboratory cell culture experiments, animal models of Parkinson’s and Multiple Sclerosis, and in humans. They completely prevent neurodegeneration in animal studies. They restore antioxidant capacity in humans. The improve cognition and mobility in humans. These studies are detailed in Dr. Goodenowe’s 2021 book, Breaking Alzheimer’s.
So, what is the full story on plasmalogen supplementation, neurodegeneration, cognition, and mobility? Join Dr. Goodenowe for Lecture 11 – The Biochemistry of Plasmalogen Supplementation and find the answers to these questions and many more. In Lecture 11 – The Biochemistry of Plasmalogen Supplementation, Dr. Goodenowe explains the relevant research and literature relating to the biochemistry of plasmalogen supplements. The lectures integrate Dr. Goodenowe’s own research and over 50 years of research from leading researchers from around the world.